Health resource utilization associated with switching to risperidone long-acting injection

Acta Psychiatrica Scandinavica

Volumn 114, Issue 1, 2006, Pages 14-20

  Young, C L ^a   Taylor, D M ^a  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Outcome assessment (healthcare); Risperdal consta; Risperidone; Schizophrenia

Indexed keywords

RISPERIDONE;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DATA ANALYSIS; FOLLOW UP; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; INJECTIONS, INTRAMUSCULAR; LENGTH OF STAY; LONDON; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT DROPOUTS; PATIENT READMISSION; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; RISPERIDONE; STATE MEDICINE;

EID: 33745092184     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2006.00766.x     Document Type: Article

References (28)

1. Lauriello J McEvoy JP Rodriguez S Bossie CA Lasser RA. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophr Res 2005 72: 249 258.
2. Lasser RA Bossie CA Gharabawi G Eerdekens M Nasrallah HA. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. J Affect Disord 2004 83: 263 275.
3. Chue P Eerdekens M Augustyns I et al. Efficacy and safety of long-acting risperidone microspheres and risperidone oral tablets. Schizophr Res 2002 3 ( Suppl. 1 174.
4. Albright PS Livingstone S Keegan DL. Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: a retrospective analysis using the Saskatchewan Health Linkable Databases. Clin Drug Investig 1996 11: 289 299.
5. Carter C Stevens M Durkin M. Effects of risperidone therapy on the use of mental health care resources in Salt Lake County, Utah. Clin Ther 1998 20: 352 363.
6. Finley PR Sommer BR Corbitt JL Brunson GH Lum BL. Risperidone: clinical outcome predictors and cost-effectiveness in a naturalistic setting. Psychopharmacol Bull 1998 34: 75 81.
7. Davis JM Matalon L Watanabe MD Blake L. Depot antipsychotic drugs. Place in therapy. Drugs 1994 47: 741 773.
8. Schooler NR. Relapse and rehospitalisation: comparing oral and depot antipsychotics. J Clin Psychiatry 2003 64: 14 17.
9. Davies LM Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry 1994 165 ( Suppl. 25 18 21.
10. Janssen Pharmaeutica. Risperdal Consta reduces schizophrenia hospital stay. Hosp Pharm Eur 2005 19: 74 75.
11. Leal A Rosillon D Mehnert A Jarema M Remington G. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiol Drug Saf 2004 13: 811 816.
12. Fleischhacker WW Eerdekens M Karcher K et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003 64: 1250 1257.
13. Guy W. ECDEU Assessment manual for psychopharmacology. Rockville, MD: US Department of Health and Human Services publication (ADM), 1976: 218 222.
14. Taylor DM Young CL Mace S Patel MX. Early clinical experience with risperidone long-acting injection: a prospective 6-month follow-up of 100 patients. J Clin Psychiatry 2004 65: 1076 1083.
15. Taylor DM Young C Patel MX. Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome. Int J Neuropsychopharmacol 2005 doi:10.1017/S1461145705006309.
16. Curtis L Neeten A. Unit Costs of Health and Social Care 2004. Canterbury, University of Kent, Personal Social Services and Research Unit, 2004.
17. Haymarket Medical Publications Ltd. Monthly Index of Medical Specialities, January 2004 edn. London: Haymarket Medical Publications Ltd, 2003.
18. World Health Organisation Collaborating Centre for Drug Statistics Methodology. ATC classification index with DDDs 2005. Oslo: World Health Organisation Collaborating Centre for Drug Statistics Methodology, 2004.
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text Revision. Washington DC: American Psychiatric Association, 2000.
20. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary, 48th edn. London: BMA and RPSGB, 2004.
21. Hayhurst KP Brown P Lewis SW. The cost-effectiveness of clozapine: a controlled, population-based mirror-image study. J Psychopharmacol 2002 16: 169 175.
22. Viale G Mechling L Maislin G Durkin M Engelhart L Lawrence BJ. Impact of risperidone on the use of mental health care resources. Psychiatr Serv 1997 48: 1153 1159.
23. Llorca PM Devos E Eerdekens M Duchesne I Leal A Mehnert A. Re-hospitalization rates with long-acting risperidone injection are lower than those reported for other antipsychotics (abstract no. P.4.E.045). Int J Neuropsychopharmacol 2002 5 ( Suppl. 1 S189.
24. Remington G Devos E Eerdekens M Duchesne I Leal A Mehnert A. Treatment with long-acting risperidone injection reduces healthcare resource use (abstract no. P.4.E.044). Int J Neuropsychopharmacol 2002 5 ( Suppl 1 S189.
25. Dickson RA Dalby JT Addington D Williams R McDougall GM. Hospital days in risperidone-treated patients. Can J Psychiatry 1999 44: 909 913.
26. Guest JF Hart WM Cookson RF Lindström E. Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. Br J Med Econ 1996 10: 59 67.
27. Lindström E Eriksson B Hellgren A Von Knorring L Eberhard G. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995 17: 402 412.
28. Schiller MJ Shumway M Hargreaves WA. Treatment costs and patient outcomes with use of risperidone in a public mental health setting. Psychiatr Serv 1999 50: 228 232.